公开(公告)号：US20190110983A1

公开(公告)日：2019-04-18

申请号：US16089194

申请日：2017-04-06

Applicant: GEDEA BIOTECH AB

Inventor： Ulf Ellervik ,  Olov Sterner ,  Helena Strevens ,  Sophie Manner

IPC: A61K9/00 ,  A61K9/02 ,  A61K9/20 ,  A61K31/7004 ,  A61K31/4174 ,  A61K31/496 ,  A61K31/4196 ,  A61K31/351 ,  A61K31/513 ,  A61K31/4164 ,  A61P31/10

Abstract: The present invention relates to a pharmaceutical formulation for vaginal administration, wherein the formulation comprises a pharmaceutical acceptable excipient and glucono δ-lactone, wherein the glucono δ-lactone is present in an amount of 5 to 99 wt % of the formulation. The invention also relates to a pharmaceutical formulation according to the invention for use in the prevention or treatment of a urogenital fungal infection. Furthermore, the invention relates to glucono δ-lactone (formula (III)), for use in the in the prevention or treatment of a fungal infection.

公开(公告)号：US11696891B2

公开(公告)日：2023-07-11

申请号：US17218739

申请日：2021-03-31

Applicant: Gedea Biotech AB

Inventor： Ulf Ellervik ,  Olov Sterner ,  Helena Strevens ,  Sophie Manner

IPC: A61K9/00 ,  A61K31/366 ,  F27D1/16 ,  F27B14/10 ,  F27B14/06 ,  A61P31/10 ,  A61K9/02 ,  H05B6/24 ,  A61K9/20 ,  A61K31/351 ,  A61K31/4164 ,  A61K31/496 ,  A61K31/513 ,  A61K31/7004 ,  F27B14/00 ,  F27B3/12 ,  A61K31/4174 ,  A61K31/4196 ,  F27B14/08

CPC classification number: A61K9/0036 ,  A61K9/0034 ,  A61K9/02 ,  A61K9/20 ,  A61K31/351 ,  A61K31/366 ,  A61K31/4164 ,  A61K31/4174 ,  A61K31/4196 ,  A61K31/496 ,  A61K31/513 ,  A61K31/7004 ,  A61P31/10 ,  F27B3/12 ,  F27B14/00 ,  F27B14/061 ,  F27B14/10 ,  F27D1/1626 ,  H05B6/24 ,  F27B2014/066 ,  F27B2014/0837

Abstract: The present invention relates to a pharmaceutical formulation for vaginal administration, wherein the formulation comprises a pharmaceutical acceptable excipient and glucono δ-lactone, wherein the glucono δ-lactone is present in an amount of 5 to 99 wt % of the formulation. The invention also relates to a pharmaceutical formulation according to the invention for use in the prevention or treatment of a urogenital fungal infection. Furthermore, the invention relates to glucono δ-lactone (formula (III)), for use in the in the prevention or treatment of a fungal infection.

公开(公告)号：US20220193031A1

公开(公告)日：2022-06-23

申请号：US17601521

申请日：2020-04-03

Applicant: GEDEA BIOTECH AB

Inventor： Ulf Ellervik ,  Sophie Manner ,  Olov Sterner ,  Helena Strevens ,  Nils-Olof Lindberg ,  Annette Säfholm

IPC: A61K31/366 ,  A61K9/00 ,  A61K9/20 ,  A61P31/04 ,  A61P31/10

Abstract: The present invention concerns a pharmaceutical composition comprising glucono-δ-lactone, which is suitable for use in the treatment of vaginal microbial infections.

公开(公告)号：US20210212937A1

公开(公告)日：2021-07-15

申请号：US17218739

申请日：2021-03-31

Applicant: Gedea Biotech AB

Inventor： Ulf Ellervik ,  Olov Sterner ,  Helena Strevens ,  Sophie Manner

IPC: A61K9/00 ,  F27D1/16 ,  F27B14/00 ,  F27B14/10 ,  H05B6/24 ,  F27B14/06 ,  F27B3/12 ,  A61K31/366 ,  A61P31/10 ,  A61K9/02 ,  A61K9/20 ,  A61K31/351 ,  A61K31/4164 ,  A61K31/4174 ,  A61K31/4196 ,  A61K31/496 ,  A61K31/513 ,  A61K31/7004

Abstract: The present invention relates to a pharmaceutical formulation for vaginal administration, wherein the formulation comprises a pharmaceutical acceptable excipient and glucono δ-lactone, wherein the glucono δ-lactone is present in an amount of 5 to 99 wt % of the formulation. The invention also relates to a pharmaceutical formulation according to the invention for use in the prevention or treatment of a urogenital fungal infection. Furthermore, the invention relates to glucono δ-lactone (formula (III)), for use in the in the prevention or treatment of a fungal infection.

公开(公告)号：US10993907B2

公开(公告)日：2021-05-04

申请号：US16089194

申请日：2017-04-06

Applicant: GEDEA BIOTECH AB

Inventor： Ulf Ellervik ,  Olov Sterner ,  Helena Strevens ,  Sophie Manner

IPC: A61K9/00 ,  A61K9/02 ,  A61K9/20 ,  A61K31/7004 ,  A61K31/4174 ,  A61K31/496 ,  A61K31/4196 ,  A61K31/351 ,  A61K31/513 ,  A61K31/4164 ,  A61P31/10 ,  F27D1/16 ,  F27B14/00 ,  F27B14/10 ,  H05B6/24 ,  F27B14/06 ,  F27B3/12 ,  A61K31/366 ,  F27B14/08

Abstract: The present invention relates to a pharmaceutical formulation for vaginal administration, wherein the formulation comprises a pharmaceutical acceptable excipient and glucono δ-lactone, wherein the glucono δ-lactone is present in an amount of 5 to 99 wt % of the formulation. The invention also relates to a pharmaceutical formulation according to the invention for use in the prevention or treatment of a urogenital fungal infection. Furthermore, the invention relates to glucono δ-lactone (formula (III)), for use in the in the prevention or treatment of a fungal infection.

公开(公告)号：US12226396B2

公开(公告)日：2025-02-18

申请号：US18163321

申请日：2023-02-02

Applicant: GEDEA BIOTECH AB

Inventor： Ulf Ellervik ,  Olov Sterner ,  Helena Strevens ,  Sophie Manner

IPC: A61K31/366 ,  A61K9/00 ,  A61K31/191 ,  A61K31/765 ,  A61K45/06 ,  A61P31/04

Abstract: Pharmaceutical compositions and methods of using said pharmaceutical compositions are provided herein. A method of preventing preterm birth in a pregnant individual is also provided, said method comprising administering to said individual a pharmaceutical composition comprising a compound of Formula XX or a lactone thereof of formula XIX or XXI and preventing said preterm birth by said administration.

公开(公告)号：US11612584B2

公开(公告)日：2023-03-28

申请号：US16753899

申请日：2018-10-05

Applicant: GEDEA BIOTECH AB

Inventor： Ulf Ellervik ,  Olov Sterner ,  Helena Strevens ,  Sophie Manner

IPC: A61K31/366 ,  A61P31/04 ,  A61K31/191 ,  A61K31/765 ,  A61K9/00 ,  A61K45/06

Abstract: The present invention concerns a pharmaceutical composition comprising a compound of Formula I for use in the treatment and/or prevention of microbial infections. Furthermore, the present invention concerns a method for prevention and/or reduction of biofilm formation.